天眼查App显示，近日，润芙荑（厦门）生物医药科技有限公司成立，法定代表人为朱茂贺，注册资本 500万人民币，由山东绚度生物科技有限公司全资持股。 企业名称润芙荑（厦门）生物医药科技有限公司法定代表人朱茂贺注册资本500万人民币国标行业科学 研究和技术服务业>研究和试验发展>工程和技术研究和试验发展地址中国（福建）自由贸易试验区厦 门片区象屿路93号厦门国际航运中心C栋4层431单元H（该住所仅限作为商事主体法律文书送达地址） 企业类型法人商事主体【有限责任公司(自然人投资或控股的法人独资)】营业期限2025-5-19至无固定期 限登记机关 来源：金融界 序号股东名称持股比例1山东绚度生物科技有限公司100% 经营范围含医学研究和试验发展；第一类医疗器械销售；第二类医疗器械销售；卫生用品和一次性使用 医疗用品销售；眼镜销售（不含隐形眼镜）；技术服务、技术开发、技术咨询、技术交流、技术转让、 技术推广；工程和技术研究和试验发展；软件销售；信息技术咨询服务；企业管理咨询；市场营销策 划；人力资源服务（不含职业中介活动、劳务派遣服务）；健康咨询服务（不含诊疗服务）；广告设 计、代理；广告制作；广告发布；保健食品（预 ...

Core Insights - The establishment of the Nanjing Biomedical Sub-center has facilitated the transfer and commercialization of research outcomes from 68 universities, resulting in 1,123 selected pharmaceutical achievements and 31 projects being established [1][2] - The sub-center has created a financial support system with a scale of 8.4 billion yuan, including various funding sources to assist startups and projects [2] Group 1 - The Nanjing Biomedical Sub-center has engaged with 68 universities and selected 1,123 pharmaceutical achievements, leading to the establishment of 31 projects [1] - The sub-center provides significant support to startups, including access to expensive laboratory equipment, which alleviates financial burdens for new companies [1] - The rapid establishment of companies, such as Innos (Nanjing) Biotechnology Co., demonstrates the effectiveness of the sub-center in facilitating research commercialization [1] Group 2 - A comprehensive financial support system of 8.4 billion yuan has been established, encompassing government funding, angel funds, and bank loans [2] - The sub-center has developed a team of over 140 technical managers to provide one-stop support for university teams, aiding in the swift establishment and growth of projects [2] - Future plans for the sub-center include enhancing collaboration with universities and enterprises to promote high-quality development in the biomedical industry [2]